Published in Medical Letter on the CDC and FDA, January 2nd, 2005
The '325 patent relates to a diagnostic kit and method of measuring the presence of both an ischemic marker and a brain endothelial cell membrane protein to indicate that a patient has suffered a stroke and, if so, whether it was an ischemic or hemorrhagic cerebral event.
In October the U.S. Patent and Trademark Office granted SynX a patent for similar claims related to the rapid, point-of-care stoke diagnostic test that the company is developing for emergency medicine.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.